| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ICU Medical, Inc.$154.42
-2.1 (-1.34%)
F 17Pipeline Score MedTech · Commercial
Market Cap
3.33 B
EPS
1.88
P/E Ratio
71.99 $
Value Trade
29.29 M
SEC Financials
Q1 2026Dilution Risk
Revenue
530.23 M
R&D Expenses
21.28 M
Operating CF
38.91 M
Total Assets
4.01 B
Total Liabilities
4.01 B
Equity
2.11 B
D/E Ratio
12,345
9.49 %
Week
3.46 %
1 Month
-11.25 %
3 Month
-1.05 %
6 Month
-34.04 %
5 Year
2,399.54 %
All Time
Cash Data
Cash Position
288.33 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
203.96 K
52 Week Range
107 - 160.29
% held by Insiders
1.92 %
% held by Institutions
103.28 %
Enterprise Value
4.38 B
Total Shares
24.99 M
Short %
7.23 %
Float Shares
24.52 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 15%
Small Cap (rank 775 of 911)
Percentile RankICU Medical, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ICUI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ICUI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ICUI▼ -1.3%today
Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America
Otsuka ICU Medical LLC has announced a significant expansion of its IV solutions manufacturing, investing over $500 million in a new facility in Austin, Texas. This expansion aims to improve supply chain resiliency and accelerate the development of non-DEHP products. It marks a key milestone in the joint venture's commitment to enhance IV solutions manufacturing in North America.
Read more →ICUIICU Medical Announces First Quarter 2026 Results
ICU Medical reported its first quarter 2026 financial results, showing a 12% decline in GAAP revenue to $530.2 million compared to the previous year. However, non-GAAP organic revenue increased by 1% when excluding the impact of the IV Solutions divestiture. The company achieved a GAAP net income of $30.1 million, a significant turnaround from a loss in the prior year. The gross margin improved to 39%, indicating better operational efficiency.
Read more →ICUIICU Medical Announces Time of First Quarter 2026 Earnings Conference Call
ICU Medical, Inc. has announced the timing for its first quarter 2026 earnings release and conference call. The earnings report will be available on May 7, 2026, followed by a conference call at 4:30 p.m. ET. This call will allow stakeholders to discuss the results and gain insights into the company's performance.
Read more →ICUIICU Medical to Participate in Upcoming Investor Conferences
ICU Medical, Inc. will participate in several upcoming investor conferences, including the Raymond James 47th Annual Institutional Investors Conference, the KeyBanc Healthcare Forum, and the 25th Annual Needham Virtual Healthcare Conference. Management will present and participate in discussions at these events, which aim to enhance investor relations and showcase the company's innovations in medical products.
Read more →ICUIICU Medical Announces Fourth Quarter 2025 Results and Provides Fiscal Year 2026 Guidance
ICU Medical, Inc. reported its financial results for the fourth quarter of 2025, revealing a revenue decline to $540.7 million compared to $629.8 million in the previous year. Despite a minor improvement in gross margin to 38%, the company experienced a GAAP net loss of $(15.7) million. Looking forward, the company has provided guidance for fiscal year 2026, estimating net income between $26 million and $44 million, alongside adjusted EBITDA projections of $400 million to $430 million. Vital Care revenue suffered a significant drop, highlighting challenges within specific product lines.
Read more →ICUIICU Medical Announces Time of Fourth Quarter 2025 Earnings Conference Call
ICU Medical, Inc. has announced the schedule for its fourth quarter 2025 earnings release and conference call. The results will be disclosed on February 19, 2026, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call will be accessible via phone and webcast, ensuring broad participation.
Read more →ICUIICU Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
ICU Medical, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference in January 2026. The presentation is scheduled for January 14 at 1:30 p.m. PT. Additionally, the company will hold one-on-one meetings with investors on the same day. The event will be webcast live and available for replay.
Read more →ICUIICU Medical to Participate at the Piper Sandler 37th Annual Healthcare Conference
ICU Medical, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. The company's management will host a fireside chat on December 4 at 10:00 a.m. PT and will also hold one-on-one meetings with investors. The event will be webcast live, with a replay available afterward.
Read more →ICUI▲ +8.1%on this news
ICU Medical Announces Third Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
ICU Medical reported its third quarter 2025 financial results, showing a revenue of $537 million, down from $589.1 million year-over-year. Despite a GAAP net loss of $3.4 million, the company improved its adjusted diluted earnings per share to $2.03. ICU Medical has updated its fiscal year 2025 guidance, projecting a reduced net loss and increased adjusted EBITDA.
Read more →ICUIICU Medical Announces Time of Third Quarter 2025 Earnings Conference Call
ICU Medical, Inc. has announced the timing for its third quarter 2025 earnings release and conference call. The earnings results will be released on November 6, 2025, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call will be accessible via phone and webcast, ensuring investor participation.
Read more →ICUIICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
ICU Medical Inc. announced its second quarter 2025 financial results, revealing revenues of $548.9 million, a decline compared to last year's $596.5 million. However, the company experienced a favorable net income of $35.3 million this quarter, a notable contrast to a loss in the same period last year. Additionally, the gross margin improved to 38%. The company has also updated its fiscal year 2025 guidance, adjusting its estimates for GAAP net loss and diluted earnings per share.
Read more →ICUIICU Medical Announces First Quarter 2025 Results
ICU Medical, Inc. reported its financial results for Q1 2025, showing a revenue increase to $604.7 million compared to $566.7 million in Q1 2024. The gross profit also rose, leading to an improved gross margin of 35%. Despite these gains, the company faced a net loss of $(15.5) million. The CEO noted that results were generally in line with expectations.
Read more →ICUIICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. have successfully formed a joint venture named Otsuka ICU Medical LLC. This partnership aims to enhance the IV solutions manufacturing capabilities in North America, combining OPF's global manufacturing expertise with ICU Medical's local production. The collaboration is expected to improve supply chain resiliency and introduce innovative technologies.
Read more →ICUIICU Medical Introduces Its New Category of Infusion Devices With FDA Clearances of Plum Solo™ and Plum Duo™ Precision IV Pumps
ICU Medical has received FDA clearance for its new Plum Solo and Plum Duo precision IV pumps, enhancing its IV Performance Platform. These devices aim to reduce infusion delivery variability and provide accurate data for patient care. The Plum Solo is a single-channel pump complementing the dual-channel Plum Duo, both ensuring ±3% accuracy in various conditions. This launch marks a significant advancement in infusion therapy technology.
Read more →ICUIICU Medical to Present at the 24th Annual Needham Virtual Healthcare Conference
ICU Medical will present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025. The presentation is scheduled for 8:00 a.m. PT and will be available via live webcast. Additionally, company management will hold one-on-one meetings on the same day, providing opportunities for direct engagement with investors.
Read more →ICUIICU Medical to Participate at the KeyBanc Healthcare Forum
ICU Medical announced its participation in the KeyBanc Healthcare Forum, scheduled for March 18-19, 2025. The company will engage in a fireside chat on March 19 at 8:15 a.m. PT and will also hold one-on-one meetings. The event will be webcast live, allowing broader access to stakeholders.
Read more →ICUIICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance
ICU Medical reported a revenue increase to $629.8 million for Q4 2024, alongside a gross profit of $227.3 million. Despite these gains, the company faced a net loss of $(23.8) million. Looking ahead, ICU Medical anticipates a net loss for fiscal year 2025, although adjusted EBITDA is projected to be between $395 million and $425 million. The company also plans to discuss these results in a conference call.
Read more →ICUIICU Medical Issues Nationwide Recall of POTASSIUM CHLORIDE INJECTION, 20 mEq and POTASSIUM CHLORIDE INJECTION, 10 mEq Due to Mislabeling ICU Medical, Inc. is voluntarily recalling one lot each of POTASSIUM CHLORIDE Inj. bags with overwrap labels 10 mEq, packaged in cases of POTASSIUM...
ICU Medical, Inc. has initiated a voluntary recall of two lots of Potassium Chloride Injection due to mislabeling. Some bags labeled as containing 10 mEq were actually filled with 20 mEq, increasing the risk of overdose if mistaken for the lower dosage. This mislabeling poses severe risks, including potential cardiac issues, particularly for vulnerable populations. The company has informed affected healthcare providers and is managing the return of the recalled products.
Read more →ICUIICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc., a Subsidiary of Otsuka Holdings Co. Ltd., Announce Creation of a Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual...
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. have announced a joint venture aimed at enhancing IV solutions manufacturing in North America. This initiative will capitalize on Otsuka's extensive manufacturing expertise and ICU Medical's distribution capabilities, creating a significant network anticipated to produce 1.4 billion IV solution units annually. The partnership is designed to address supply chain challenges and innovate product offerings, with an initial investment of $200 million from Otsuka. Both companies will collaborate towards FDA approvals for overseas manufacturing sites and expedite new product development.
Read more →ICUIICU Medical Announces Third Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance
ICU Medical reported its third quarter 2024 financial results, demonstrating an increase in revenue year-over-year to $589.1 million. However, the company faced significant challenges, recording a GAAP net loss of $(33.0) million compared to a net income in the prior year. Moreover, ICU Medical adjusted its fiscal year 2024 guidance, increasing its projected loss estimates, which indicates a potential downturn in performance. While revenue and gross profits showed positive growth, the overall outlook was marred by the increasing losses.
Read more →ICUIICU Medical Announces Second Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance
ICU Medical, Inc. announced its financial results for the second quarter of 2024, reporting a revenue increase to $596.5 million compared to $549.3 million in the previous year. However, the company also experienced a larger GAAP net loss of $(21.4) million, indicating challenges despite the revenue growth. Additionally, ICU Medical updated its fiscal guidance for 2024, suggesting a higher range for expected net losses and lower adjusted EBITDA projections.
Read more →ICUIICU Medical Announces First Quarter 2024 Results
ICU Medical reported its financial results for the first quarter of 2024, showing a slight decline in revenue to $566.7 million compared to $568.6 million in Q1 2023. The net loss increased significantly to $39.5 million from the previous year's loss of $9.8 million, alongside a decrease in GAAP gross profit and adjusted diluted earnings per share. These results indicate challenges in the company's performance compared to prior periods, prompting attention from investors and stakeholders.
Read more →ICUIICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal Year 2024 Guidance
ICU Medical, Inc. announced its financial results for Q4 2023, reporting revenue of $587.9 million, a slight increase from $578.0 million in Q4 2022. Despite this revenue growth, the company experienced a net loss of $(17.1) million, worsening from $(15.5) million in the prior year. For FY 2024, ICU Medical provided guidance estimating net losses between $(88) million to $(71) million, but anticipates adjusted EBITDA ranging from $330 million to $370 million. The company continues to focus on innovation and value in its medical products.
Read more →ICUIICU Medical Announces Third Quarter 2023 Results
ICU Medical, Inc. reported its financial results for the third quarter of 2023, showing a revenue decrease to $553.3 million from $597.9 million in Q3 2022. Despite this decline in overall revenue, the company achieved a net income of $7.2 million, contrasting with a loss from the previous year. The gross margin improved to 33%, a notable rise from 31% year-on-year. However, adjusted diluted earnings per share fell from $1.75 to $1.57, signaling profitability challenges. The company also noted a decrease in revenues across various product lines, particularly consumables and vital care segments.
Read more →ICUI▲ +6.1%on this news
ICU Medical Receives FDA Clearance for Plum Duo™ Infusion Pump and LifeShield™ Infusion Safety Software
ICU Medical has received FDA 510(k) clearance for its Plum Duo infusion pump and LifeShield infusion safety software. Set to launch in early 2024, the Plum Duo enhances medication delivery with a user-friendly interface and advanced safety features. This development aligns with ICU Medical's vision of integrating best-in-class devices into a cohesive platform for improved patient care.
Read more →ICUIICU Medical Announces Second Quarter 2023 Results and Narrows Fiscal Year 2023 Guidance Ranges
ICU Medical, Inc. reported its financial results for the second quarter of 2023, with revenue totaling $549.3 million, a decrease from $561 million in the same quarter last year. The company achieved a GAAP gross margin of 35%, up from 30% year-over-year, and reported an adjusted diluted earnings per share of $1.88, an increase from $1.37 a year prior. However, ICU Medical also faced a net loss of $(9.9) million and has narrowed its fiscal year guidance for adjusted EBITDA and diluted earnings per share, indicating challenges in achieving growth in some product lines.
Read more →ICUIICU Medical Announces First Quarter 2023 Results
ICU Medical, Inc. released its financial results for the first quarter of 2023, reporting a revenue increase to $568.6 million compared to $543.1 million in the same period the previous year. The company demonstrated enhanced profitability with a gross profit of $192.0 million and improved adjusted EBITDA of $102.0 million. However, a GAAP net loss of $(9.8) million was reported, though this marks a significant reduction from last year's loss of $(38.1) million. Key challenges remain, including potential impacts from foreign currency fluctuations and the ongoing COVID-19 pandemic.
Read more →ICUIICU Medical Announces Fourth Quarter 2022 Results and Provides Fiscal Year 2023 Guidance
ICU Medical, Inc. announced its financial results for Q4 2022, showing a revenue increase to $578 million. However, the company reported a GAAP net loss of $15.5 million for the quarter and a decrease in gross margin. For FY 2023, ICU Medical expects further losses, estimating a GAAP net loss between $(73) to $(37) million. Improved operational results from the recently acquired Smiths Medical business were noted, alongside a significant rise in adjusted EBITDA.
Read more →ICUIICU Medical's Plum 360™ Infusion System First-Ever to Receive Best in KLAS Honors as the Top-Performing Smart Pump in both EMR-Integrated and Traditional Categories
ICU Medical's Plum 360 smart infusion system has been awarded Best in KLAS for the sixth consecutive year, marking it as the top-performing smart pump in both EMR-Integrated and Traditional categories. This recognition underscores the system's alignment with industry guidelines and its capabilities in improving patient safety and care quality. The dual awards highlight ICU Medical's commitment to service excellence.
Read more →ICUISmiths Medical Issues Urgent Medical Device Correction Letter Notifying Customers of Potential Issues with CADD™ Infusion System Infusion Sets for use with CADD pumps Smiths Medical issued an Urgent Medical Device Correction Letter to notify affected customers of two potential issues with CADDTM Infusion System...
MINNEAPOLIS , Dec. 12, 2022 /PRNewswire/ -- Smiths Medical issued an Urgent Medical Device Correction Letter to notify affected customers of two potential issues with CADD TM Infusion System Infusion Sets related to potential lack of delivery or underdelivery and false no disposa
Read more →ICUIICU Medical Announces Third Quarter 2022 Results The Company Reaffirms 2022 Fiscal Year Guidance
ICU Medical Announces Third Quarter 2022 Results The Company Reaffirms 2022 Fiscal Year Guidance SAN CLEMENTE, Calif., November 7, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq ICUI), a leader in the development, manufacture and sale of innovative medical products, today a
Read more →ICUIICU Medical Announces Second Quarter 2022 Results Company Updated FY 2022 Guidance
ICU Medical Announces Second Quarter 2022 Results Company Updated FY 2022 Guidance SAN CLEMENTE, Calif., August 8, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financi
Read more →ICUIICU Medical Announces First Quarter 2022 Results
ICU Medical Announces First Quarter 2022 Results SAN CLEMENTE, Calif., May 9, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended March
Read more →ICUIICU Medical Announces Fourth Quarter 2021 Results and Provides Fiscal Year 2022 Guidance
ICU Medical Announces Fourth Quarter 2021 Results and Provides Fiscal Year 2022 Guidance SAN CLEMENTE, Calif., February 24, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq ICUI), a leader in the development, manufacture and sale of innovative medical products, today announce
Read more →ICUIICU Medical Completes the Acquisition of Smiths Medical from Smiths Group plc
ICU Medical has completed its acquisition of Smiths Medical from Smiths Group plc, creating a leading infusion therapy company with an estimated combined revenue of $2.5 billion. The acquisition is expected to enhance ICU Medical's market position and stability in the medical supply chain. CEO Vivek Jain expressed optimism about the integration and future growth opportunities.
Read more →ICUIICU Medical, Inc. Announces Third Quarter 2021 Results
ICU Medical, Inc. Announces Third Quarter 2021 Results SAN CLEMENTE, Calif., November 3, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applicat
Read more →ICUI▲ +26.2%on this news
ICU Medical Inc. to Acquire Smiths Medical
ICU Medical Inc. to Acquire Smiths Medical September 8, 2021 1 Cautionary Statements Regarding Forward-Looking Information & GAAP to Non-GAAP Financial Measures > This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 19
Read more →ICUIICU Medical Issues a Voluntary Nationwide Recall of Aminosyn II 15%, An Amino Acid Injection, Sulfite Free IV Solution Due to the Presence of Particulate Matter
ICU Medical has voluntarily recalled one lot of Aminosyn II, 15%, an amino acid injection, due to visible particulate matter found in the solution. The recall affects 2,112 units and was initiated after routine inspections revealed fibers, hair, and proteinaceous material. Although no adverse events have been reported, the presence of particulate matter poses risks such as inflammation and blood clots.
Read more →ICUIICU Medical, Inc. Announces Second Quarter 2021 Results Company Updated FY 2021 Guidance
ICU Medical, Inc. Announces Second Quarter 2021 Results Company Updated FY 2021 Guidance SAN CLEMENTE, Calif., August 4, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion t
Read more →ICUIICU Medical, Inc. Announces First Quarter 2021 Results
ICU Medical, Inc. Announces First Quarter 2021 Results SAN CLEMENTE, Calif., May 6, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications,
Read more →ICUIICU Medical, Inc. Announces Fourth Quarter 2020 Results and Provides Fiscal Year 2021 Guidance
ICU Medical, Inc. Announces Fourth Quarter 2020 Results and Provides Fiscal Year 2021 Guidance SAN CLEMENTE, Calif., February 25, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq ICUI), a leader in the development, manufacture and sale of innovative medical products used in i
Read more →ICUIICU Medical's Plum 360™ Infusion System Receives First-Ever Best in KLAS Honor as Top-Performing Smart Pump EMR-Integrated ICU Medical Inc., a worldwide leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical...
SAN CLEMENTE, Calif. , Feb. 2, 2021 /PRNewswire/ -- ICU Medical Inc. , a worldwide leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications, today announced its Plum 360 smart infusion system is the firs
Read more →ICUIICU Medical, Inc. Announces Third Quarter 2020 Results and Updates Fiscal Year 2020 Guidance
ICU Medical, Inc. Announces Third Quarter 2020 Results and Updates Fiscal Year 2020 Guidance SAN CLEMENTE, Calif., November 5, 2020 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq ICUI), a leader in the development, manufacture and sale of innovative medical products used in infus
Read more →ICUIICU Medical Broadens its Non-PVC/Non-DEHP IV Solutions Portfolio by Entering Long-Term U.S. Distribution Agreement with Grifols for Certain Core IV Solution Products ICU Medical Inc. (NASDAQ: ICUI) today announced that it has entered into a long-term agreement with Grifols to distribute a full line of...
SAN CLEMENTE, Calif., Aug. 10, 2020 /PRNewswire/ -- ICU Medical Inc. (NASDAQ: ICUI ) today announced that it has entered into a long-term agreement with Grifols to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection, USP to customers in the
Read more →ICUIICU Medical, Inc. Announces Second Quarter 2020 Results
ICU Medical, Inc. Announces Second Quarter 2020 Results SAN CLEMENTE, Calif., August 10, 2020 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applicat
Read more →ICUIICU Medical Issues a Voluntary Nationwide Recall of Lactated Ringer's Injection, USP Due to the Presence of Particulate Matter ICU Medical, Inc. is voluntarily recalling one single lot of Lactated Ringer's Injection, USP. The products are being recalled to the hospital/user...
LAKE FOREST, Ill. , May 8, 2020 /PRNewswire/ -- ICU Medical, Inc. is voluntarily recalling one single lot of Lactated Ringer's Injection, USP. The products are being recalled to the hospital/user level due to the presence of particulate matter identified as iron oxide. ICU Medica
Read more →ICUIICU Medical, Inc. Announces First Quarter 2020 Results and Updates Fiscal Year 2020 Guidance
ICU Medical, Inc. Announces First Quarter 2020 Results and Updates Fiscal Year 2020 Guidance SAN CLEMENTE, Calif., May 7, 2020 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion t
Read more →ICUIICU Medical, Inc. Announces Fourth Quarter 2019 Results
ICU Medical, Inc. Announces Fourth Quarter 2019 Results SAN CLEMENTE, Calif., February 27, 2020 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applic
Read more →ICUIICU Medical, Inc. Announces Third Quarter 2019 Results
ICU Medical, Inc. Announces Third Quarter 2019 Results SAN CLEMENTE, Calif., November 11, 2019 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applica
Read more →ICUIICU Medical, Inc. to Acquire Pursuit Vascular, Inc. ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and...
SAN CLEMENTE, Calif. , Nov. 4, 2019 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, announced today that it has entered into a definitive a
Read more →ICUIICU Medical, Inc. Issues a Voluntary Nationwide Recall of Lactated Ringer's Injection, USP and 0.9% Sodium Chloride Injection, USP Due to Presence of Particulate Matter ICU Medical, Inc. (Nasdaq: ICUI) is voluntarily recalling one single lot of Lactated Ringer's Injection, USP, and one single lot of 0.9% Sodium...
LAKE FOREST, Ill. , Oct. 30, 2019 /PRNewswire/ -- ICU Medical, Inc. (Nasdaq: ICUI ) is voluntarily recalling one single lot of Lactated Ringer's Injection, USP, and one single lot of 0.9% Sodium Chloride Injection, USP. The products are being recalled to the hospital level due to
Read more →ICUIICU Medical Issues a Voluntary Nationwide Recall of Certain Lots of Plum and Sapphire Microbore Infusion Sets with Inline Filters ICU Medical, Inc. (Nasdaq: ICUI) announced a voluntary recall on 29 July 2019 of certain lots of Plum and Sapphire Microbore Infusion Sets with...
SAN CLEMENTE, Calif. , Oct. 7, 2019 /PRNewswire/ -- ICU Medical, Inc. (Nasdaq: ICUI ) announced a voluntary recall on 29 July 2019 of certain lots of Plum and Sapphire Microbore Infusion Sets with inline filters due to the potential for small amounts of fluid leaking out of the a
Read more →ICUIICU Medical, Inc. Announces Second Quarter 2019 Results Company Updates FY 2019 Guidance
ICU Medical, Inc. Announces Second Quarter 2019 Results Company Updates FY 2019 Guidance SAN CLEMENTE, Calif., August 7, 2019 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion t
Read more →ICUIICU Medical CFO Announces Intention to Retire from CFO Role After Close of FY19
ICU Medical CFO Announces Intention to Retire from CFO Role After Close of FY19 SAN CLEMENTE, Calif., July 8, 2019 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and cr
Read more →ICUIICU Medical, Inc. Announces First Quarter 2019 Results
ICU Medical, Inc. Announces First Quarter 2019 Results SAN CLEMENTE, Calif., May 9, 2019 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications,
Read more →ICUIICU Medical, Inc. Announces Fourth Quarter 2018 Results
ICU Medical, Inc. Announces Fourth Quarter 2018 Results SAN CLEMENTE, Calif., February 28, 2019 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applica
Read more →ICUIICU Medical Issues a Voluntary Nationwide Recall of Certain Lots of ChemoLock™ and ChemoClave® Vial Spikes Due to the Potential for Burr Particulate ICU Medical, Inc. today announced a voluntary recall of certain lots of ChemoLock™ and ChemoClave® Vial Spikes due to the potential for burr...
SAN CLEMENTE, Calif. , Feb. 25, 2019 /PRNewswire/ -- ICU Medical, Inc. today announced a voluntary recall of certain lots of ChemoLock™ and ChemoClave ® Vial Spikes due to the potential for burr particulate originating from the protective cap used in the assembly of the device. T
Read more →ICUIPfizer Infusion Systems (A Business Unit of Pfizer Inc.) Combined Statements of Income (Loss) and Comprehensive Income (Loss), Business Unit Equity, and Cash Flows for the years ended
Pfizer Infusion Systems (A Business Unit of Pfizer Inc.) Combined Statements of Income (Loss) and Comprehensive Income (Loss), Business Unit Equity, and Cash Flows for the years ended December 31, 2016 and 2015 with Independent Auditors Report Thereon Pfizer Infusion System
Read more →ICUIICU Medical, Inc. Announces Third Quarter 2018 Results Company Modifies FY 2018 Guidance and Provides Initial FY 2019 Adjusted EBITDA Guidance
ICU Medical, Inc. Announces Third Quarter 2018 Results Company Modifies FY 2018 Guidance and Provides Initial FY 2019 Adjusted EBITDA Guidance SAN CLEMENTE, Calif., November 8, 2018 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture an
Read more →ICUIICU Medical, Inc. Announces Second Quarter 2018 Results Company Updates FY 2018 Guidance
ICU Medical, Inc. Announces Second Quarter 2018 Results Company Updates FY 2018 Guidance SAN CLEMENTE, Calif., August 9, 2018 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion t
Read more →ICUIICU Medical's Plum 360 Infusion System is the First Medical Device to Earn UL Cybersecurity Assurance Program (UL CAP) Certification ICU Medical, Inc., a worldwide leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical...
SAN CLEMENTE, Calif. , June 19, 2018 /PRNewswire/ -- ICU Medical, Inc. , a worldwide leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications, has become the first medical device manufacturer to obtain c
Read more →ICUIICU Medical, Inc. Announces First Quarter 2018 Results
ICU Medical, Inc. Announces First Quarter 2018 Results SAN CLEMENTE, Calif., May 9, 2018 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications,
Read more →ICUIICU Medical, Inc. Announces Fourth Quarter and Fiscal Year 2017 Results Company Updates FY 2018 Adjusted EPS Guidance
ICU Medical, Inc. Announces Fourth Quarter and Fiscal Year 2017 Results Company Updates FY 2018 Adjusted EPS Guidance SAN CLEMENTE, Calif., March 1, 2018 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical
Read more →ICUIICU Medical, Inc. Announces Third Quarter 2017 Results Company Updates FY 2017 Guidance and Provides Initial FY 2018 EBITDA and Adjusted EPS Guidance
ICU Medical, Inc. Announces Third Quarter 2017 Results Company Updates FY 2017 Guidance and Provides Initial FY 2018 EBITDA and Adjusted EPS Guidance SAN CLEMENTE, Calif., November 9, 2017 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufac
Read more →ICUIICU Medical, Inc. Announces Second Quarter 2017 Results
ICU Medical, Inc. Announces Second Quarter 2017 Results SAN CLEMENTE, Calif., August 9, 2017 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applicatio
Read more →ICUIICU Medical Issues a Voluntary Nationwide Recall of One Lot of 0.9% Sodium Chloride Injection Due to the Presence of Particulate Matter ICU Medical, Inc. is voluntarily recalling one lot of 0.9% Sodium Chloride Injection, USP 1000 mL to the hospital/user level due to a confirmed...
LAKE FOREST, Ill. , July 28, 2017 /PRNewswire/ -- ICU Medical, Inc. is voluntarily recalling one lot of 0.9% Sodium Chloride Injection, USP 1000 mL to the hospital/user level due to a confirmed customer complaint of particulate matter identified as stainless steel within a single
Read more →ICUIICU Medical, Inc. Announces First Quarter 2017 Results
ICU Medical, Inc. Announces First Quarter 2017 Results SAN CLEMENTE, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications,
Read more →ICUIIntegrating ICU Medical Infusion Devices with Hospital Electronic Medical Records Decreased Major Dosing Errors by 52 Percent ICU Medical, Inc. (NASDAQ: ICUI), a leader in innovative medical devices for infusion therapy, oncology and critical care, today announced results of ...
SAN CLEMENTE, Calif. , Feb. 15, 2017 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ), a leader in innovative medical devices for infusion therapy, oncology and critical care, today announced results of a new multi-hospital study that shows dramatic improvements in potentially c
Read more →ICUIICU Medical, Inc.
ICU Medical, Inc. Provides Update on Hospira Infusion Systems Transaction SAN CLEMENTE, Calif., January 5, 2017 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ: ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncolog
Read more →ICUIICU Medical Launches the All-New Diana™ Compounding Workflow System at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Las Vegas ICU Medical, Inc. (NASDAQ: ICUI) today announced the launch of the all-new Diana™ compounding workflow system at the American Society of...
SAN CLEMENTE, Calif. , Dec. 1, 2016 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced the launch of the all-new Diana™ compounding workflow system at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting and Exhibition in Las Vegas December 5-7,
Read more →ICUIICU Medical Inc.
ICU Medical Inc. to Acquire the Hospira Infusion Systems Business from Pfizer Inc. for $1 Billion in Cash and Stock The addition of Hospira's IV pumps, solutions, and devices business to ICU Medical's existing portfolio will create a leading pure-play infusion therapy company
Read more →ICUIB. Braun and ICU Medical Sign Expanded Long-Term International Distribution Agreement ICU Medical Inc. (NASDAQ: ICUI) today announced that it has entered into a long-term distribution agreement with B. Braun Melsungen AG, giving B....
SAN CLEMENTE, Calif. , March 21, 2016 /PRNewswire/ -- ICU Medical Inc. (NASDAQ: ICUI ) today announced that it has entered into a long-term distribution agreement with B. Braun Melsungen AG , giving B. Braun distribution rights to promote ICU Medical's SwabCap ® disinfecting cap
Read more →ICUINew Study Shows ICU Medical's SwabCap® Reduced Central Line-Associated Bloodstream Infections and Blood Culture Contamination, Corresponding To $3.2 Million Annual Savings ICU Medical Inc. (NASDAQ: ICUI) today announced that a new study published in the December 2015 issue of the peer-reviewed journal Infection Control...
SAN CLEMENTE, Calif. , Jan. 13, 2016 /PRNewswire/ -- ICU Medical Inc. (NASDAQ: ICUI ) today announced that a new study published in the December 2015 issue of the peer-reviewed journal Infection Control & Hospital Epidemiology showed that the company's SwabCap® disinfecting cap f
Read more →ICUIBuy-OUT AGREEMENT THIS BUY-OUT AGREEMENT, dated as of
THIS BUY-OUT AGREEMENT, dated as of September 30, 2015 (this "Agreement"), is entered into by and between ICU Medical, Inc., a Delaware corporation ("Employer"), and George A. Lopez, M.D. ("Employee"). Employer and Employee are sometimes referred to herein as the "Parties". Acco
Read more →ICUINew Clinical Study Shows ICU Medical Infusion Systems Are Associated with a Reduction in Both Hazardous Drug Exposure and Central Line-Associated Bloodstream Infections ICU Medical, Inc. (NASDAQ: ICUI) today announced that a new study presented this week at the 38th Annual Association of Pediatric Hematology/Oncology ...
SAN CLEMENTE, Calif. , Sept. 5, 2014 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that a new study presented this week at the 38 th Annual Association of Pediatric Hematology/Oncology Nurses (APHON) Conference in Portland, OR showed that the company's ChemoCl
Read more →ICUINew Study Shows ICU Medical's MicroClave and Neutron Needlefree IV Connectors Have Significantly Lower Bacterial Transfer Rate Than All Other Connectors Tested ICU Medical, Inc. (NASDAQ: ICUI) today announced that results of a clinically simulated in-vitro study presented at the 3rd World Congress of...
BERLIN , June 18, 2014 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that results of a clinically simulated in-vitro study presented at the 3 rd World Congress of Vascular Access in Berlin Germany June 18-20, 2014 showed that the ICU Medical MicroClave ® neutr
Read more →ICUINew Peer-Reviewed Study Shows ICU Medical's Tego® Needlefree Connector is Associated with a 10-12% Reduction of Catheter-Related Bloodstream Infections in Hemodialysis Patients ICU Medical, Inc. (NASDAQ: ICUI) today announced that a new peer-reviewed study in the April 2014 issue of the International Journal of Nephrology...
SAN CLEMENTE, Calif. , April 23, 2014 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that a new peer-reviewed study in the April 2014 issue of the International Journal of Nephrology and Renovascular Disease shows that the use of the company's Tego ® needlefree
Read more →ICUINew Clinical Studies Show ICU Medical's ChemoLock™ Closed System Transfer Device Prevents Hazardous Drug Surface Contamination and Provides a Completely Dry Disconnect ICU Medical, Inc. (NASDAQ: ICUI) today announced that two new studies presented yesterday at the American Society of Health-System Pharmacists (ASHP) ...
ORLANDO, Fla. , Dec. 12, 2013 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that two new studies presented yesterday at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting and Exhibition in Orlando demonstrated that the company's newly lau
Read more →ICUIICU Medical Launches the ChemoLock™ Needlefree Closed System Transfer Device (CSTD) at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting ICU Medical, Inc. (NASDAQ: ICUI) today announced that will formally launch the ChemoLockTM needlefree closed system transfer device (CSTD) at the...
ORLANDO, Fla. , Dec. 9, 2013 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that will formally launch the ChemoLock TM needlefree closed system transfer device (CSTD) at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting and Exhibition in
Read more →ICUIICU Medical Receives Premier Inc. Contract for the New Diana™ Hazardous Drug Compounding System with Barcode Scanning ICU Medical Inc. (NASDAQ: ICUI) today announced it has been awarded a six-year group purchasing contract from Premier Inc. for the DianaTM hazardous...
SAN CLEMENTE, Calif. , Dec. 2, 2013 /PRNewswire/ -- ICU Medical Inc. (NASDAQ: ICUI ) today announced it has been awarded a six-year group purchasing contract from Premier Inc. for the Diana TM hazardous drug compounding system , the world's first user-controlled, automated steril
Read more →ICUITwo New Clinical Studies Show ICU Medical ChemoClave® System Improves Safety by Reducing Hazardous Drug Exposure and Eliminating Accidental Disconnects ICU Medical, Inc. (NASDAQ: ICUI) today announced that two new studies presented this week at the 37th Annual Association of Pediatric...
SAN CLEMENTE, Calif. , Sept. 19, 2013 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that two new studies presented this week at the 37 th Annual Association of Pediatric Hematology/Oncology Nurses (APHON) Annual Conference in Louisville, KY showed that the com
Read more →ICUIICU Medical's New ChemoLock™ Needlefree Closed System Transfer Device (CSTD) Receives First-Ever FDA 510(k) Clearances for Both Pharmacy and Patient Administration Applications ICU Medical, Inc. (NASDAQ: ICUI) today announced that its ChemoLock™ needlefree closed system transfer device (CSTD) is the first and only CSTD to...
SAN CLEMENTE, Calif. , Sept. 9, 2013 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that its ChemoLock ™ needlefree closed system transfer device (CSTD) is the first and only CSTD to receive United States Food and Drug Administration (FDA) 510(k) clearance for
Read more →ICUIICU Medical Receives Premier Healthcare Alliance Contracts for its Complete Line of Needlefree IV Connectors, Sets and Accessories ICU Medical, Inc. (NASDAQ: ICUI) today announced that it has received two separate six-year group purchasing contracts from the Premier healthcare...
(Logo: http://photos.prnewswire.com/prnh/20120906/LA68795LOGO ) The new contract also marks the first time that ICU Medical's complete line of needlefree IV connectors —which includes the Neutron ® catheter patency device, the MicroClave ® and MicroClave Clear neutral displaceme
Read more →ICUIICU Medical Announces European Launch of the New Diana™ Automated Hazardous Drug Compounding System ICU Medical, Inc. (NASDAQ: ICUI) today announced the European launch of a new version of Diana Hazardous Drug Compounding System at the European...
SAN CLEMENTE, Calif. , March 12, 2013 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced the European launch of a new version of Diana Hazardous Drug Compounding System at the European Association of Hospital Pharmacists (EAHP) 18th Congress in Paris, France March
Read more →ICUINew U.S. Market Data Shows ICU Medical's Needlefree IV Connector Technology Chosen More than Twice as Often as Any Other ICU Medical, Inc. (NASDAQ:ICUI) today announced that its family of needlefree intravenous (IV) connectors was chosen by U.S. healthcare providers...
SAN CLEMENTE, Calif. , March 7, 2013 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that its family of needlefree intravenous (IV) connectors was chosen by U.S. healthcare providers more than twice as often as any other connector technology according to newly r
Read more →ICUIICU Medical, Inc. to Voluntarily Discontinue U.S. Distribution of the CLC2000 Positive Displacement Needlefree IV Connector ICU Medical, Inc. (NASDAQ: ICUI) today announced it will voluntarily discontinue U.S. distribution of the CLC2000® Positive Displacement Needlefree...
SAN CLEMENTE, Calif. , Jan. 28, 2013 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced it will voluntarily discontinue U.S. distribution of the CLC2000® Positive Displacement Needlefree Connector effective April 30, 2013 due to FDA concerns over the safety of posi
Read more →ICUIICU Medical Launches CardioFlo™ Minimally Invasive Hemodynamic Monitoring Sensor System ICU Medical, Inc. (Nasdaq: ICUI) today announced it will launch the CardioFlo hemodynamic monitoring sensor system at the Society of Critical Care...
SAN CLEMENTE, Calif. , Jan.17, 2013 /PRNewswire/ -- ICU Medical, Inc. (Nasdaq: ICUI ) today announced it will launch the CardioFlo hemodynamic monitoring sensor system at the Society of Critical Care Medicine (SCCM) Critical Care Congress in San Juan, Puerto Rico , January 19-23,
Read more →ICUIICU Medical Launches Diana™ Automated Sterile Compounding System for the Accurate, Safe, and Efficient Preparation of Hazardous Drugs ICU Medical, Inc. (NASDAQ: ICUI) today announced the U.S. launch of the Diana Hazardous Drug Compounding System at the American Society of Health...
SAN CLEMENTE, Calif. , Nov. 29, 2012 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced the U.S. launch of the Diana Hazardous Drug Compounding System at the American Society of Health System Pharmacists (ASHP) Midyear Meeting and Exposition in Las Vegas December 2
Read more →ICUIICU Medical's Diana™ System May Help Compounding Pharmacies Avoid Drug Contamination A recent high-profile incident involving drug contamination and patient deaths associated with a compounding pharmacy underscores the safety...
SAN CLEMENTE, Calif. , Oct. 22, 2012 /PRNewswire/ -- A recent high-profile incident involving drug contamination and patient deaths associated with a compounding pharmacy underscores the safety challenges associated with current drug compounding processes throughout the country.
Read more →ICUIICU Medical Launches NanoClave™ Needlefree Connector to Help Clinicians Better Manage Neonatal and Pediatric Patient Fluids ICU Medical, Inc. (Nasdaq:ICUI) today announced the introduction of the NanoClave low-profile neutral displacement needlefree connector, designed to...
SAN CLEMENTE, Calif. , Oct. 15, 2012 /PRNewswire/ -- ICU Medical, Inc. (Nasdaq: ICUI ) today announced the introduction of the NanoClave low-profile neutral displacement needlefree connector, designed to keep neonatal and pediatric patients safe by minimizing flush volumes while
Read more →ICUISafe Handling Presentation Hosted by ICU Medical Will Teach Nurses How To Protect Themselves From Exposure to Hazardous Drugs ICU Medical, Inc. (Nasdaq:ICUI) today announced they will be hosting a presentation by Seth Eisenberg, RN, OCN®, titled Nurse Safety with Hazardous...
SAN CLEMENTE, Calif. , Sept. 6, 2012 /PRNewswire/ -- ICU Medical, Inc. (Nasdaq: ICUI ) today announced they will be hosting a presentation by Seth Eisenberg, RN , OCN ® , titled "Nurse Safety with Hazardous Drugs: Where Do You Stand?" to educate nurses about the dangers of exposu
Read more →ICUIICU Medical, Inc. Signs Agreement with ROi for MicroClave® Clear Needlefree IV Connector ICU Medical, Inc. (NASDAQ: ICUI) today announced that it has signed a contract with ROi (Resource Optimization & Innovation) for MicroClave® Clear...
SAN CLEMENTE , Cali , June 26, 2012 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that it has signed a contract with ROi (Resource Optimization & Innovation) for MicroClave ® Clear neutral displacement needlefree IV connectors to be used on central and periphe
Read more →ICUIICU Medical's Custom IV System with MicroClave® Needlefree Connector Shown to Help Reduce NICU Infection Rates and Medication Errors ICU Medical, Inc. (NASDAQ: ICUI) announced today that a clinical case study prepared by clinicians from Women & Infants Hospital in Providence, R.I....
SAN CLEMENTE, Calif. , June 13, 2012 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) announced today that a clinical case study prepared by clinicians from Women & Infants Hospital in Providence, R.I. showed that a collaboratively-developed custom IV system featuring the MicroC
Read more →ICUIICU Medical's ChemoClave™ System Included in Mobius Therapeutics' Mitosol® Kit for Use in Glaucoma Surgery ICU Medical, Inc. (NASDAQ: ICUI) and Mobius Therapeutics, LLC today jointly announced that ICU Medical's ChemoClave™ system for the safe handling of...
SAN CLEMENTE, Calif. and ST. LOUIS , June 7, 2012 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) and Mobius Therapeutics, LLC today jointly announced that ICU Medical's ChemoClave ™ system for the safe handling of hazardous drugs will be packaged with Mobius Therapeutics' Mito
Read more →ICUIICU Medical, Inc. Plans to Vigorously Seek to Collect Damages in wake of Patent Infringement Victory Over RyMed Technologies ICU Medical, (NASDAQ:ICUI) today announced that it would vigorously seek to collect damages as a result of its patent infringement victory over...
SAN CLEMENTE, Calif. , May 14, 2012 /PRNewswire/ -- ICU Medical, (NASDAQ: ICUI ) today announced that it would "vigorously seek to collect damages" as a result of its patent infringement victory over RyMed. ICU Medical filed a lawsuit in 2007 to stop RyMed Technologies from selli
Read more →ICUIBreaking Studies: ICU Medical Inc.'s ChemoClave™ System Shown to Protect Nurses from Exposure to Hazardous Drugs While Increasing Nurse Satisfaction ICU Medical, Inc. (NASDAQ: ICUI) today announced that two studies presented this week at the 37th Annual Congress of the Oncology Nursing Society...
NEW ORLEANS , May 3, 2012 /PRNewswire-FirstCall/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that two studies presented this week at the 37th Annual Congress of the Oncology Nursing Society (ONS) in New Orleans show that the company's ChemoClave™ needlefree closed system
Read more →ICUIBreaking Study: ICU Medical's Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks ICU Medical, Inc. (NASDAQ: ICUI) announced that a clinical study presented at the American Society of Nephrology's (ASN) Kidney Week 2011 showed the...
SAN CLEMENTE, Calif. , Dec. 13, 2011 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) announced that a clinical study presented at the American Society of Nephrology's (ASN) Kidney Week 2011 showed the Tego ® needlefree hemodialysis connector can decrease heparin use and reduce
Read more →ICUINovation Awards ICU Medical, Inc. a New Contract to Supply Members With a Complete Line of Clinically-Preferred Critical Care Products ICU Medical, Inc. (NASDAQ: ICUI) today announced it has been awarded a 36-month contract with Novation for its full line of Critical Care products,...
SAN CLEMENTE, Calif. , Nov. 15, 2011 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced it has been awarded a 36-month contract with Novation for its full line of Critical Care products, including hemodynamic monitors and catheters, disposable pressure transducers,
Read more →ICUIBreaking Study: ICU Medical, Inc. ChemoClave® System Costs Less to Implement than any Closed System Transfer Device for the Safe Handling of Hazardous Drugs ICU Medical, Inc. (NASDAQ: ICUI) today announced that a study presented this past weekend at the 36th annual meeting of the California Society of...
SAN CLEMENTE, Calif. , Nov. 8, 2011 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that a study presented this past weekend at the 36th annual meeting of the California Society of Health-System Pharmacists (CSHP) in Anaheim, CA has shown that the company's Chem
Read more →ICUIICU Medical Launches Neutron™ Needlefree Catheter Patency Device With Constant Neutral Pressure Backed by a $100,000 Guarantee to Reduce Catheter Occlusions ICU Medical, Inc. (NASDAQ: ICUI) announced it is launching the Neutron™ needlefree catheter patency device with constant neutral pressure today at...
SAN JOSE, Calif. , Oct. 4, 2011 / PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) announced it is launching the Neutron ™ needlefree catheter patency device with constant neutral pressure today at the Association for Vascular Access Annual Scientific Meeting in San Jose, CA. Neu
Read more →ICUIICU Medical, Inc. Awarded Hemodynamic Monitoring Agreement by the Premier Healthcare Alliance and Named Single-Source Supplier of Hemodynamic Monitoring Products to the ASCEND® Program ICU Medical, Inc. (NASDAQ: ICUI) today announced it has been awarded a 36-month contract with Premier Purchasing Partners, L.P., the group purchasing ...
SAN CLEMENTE, Calif. , April 14, 2011 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced it has been awarded a 36-month contract with Premier Purchasing Partners, L.P., the group purchasing unit of Premier Inc., for its hemodynamic monitoring products, which are mo
Read more →ICUIThree Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections ICU Medical, Inc. (NASDAQ: ICUI) today announced that three different clinical studies presented at the Annual Scientific Meeting of the Society for...
SAN CLEMENTE, Calif. , April 4, 2011 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI ) today announced that three different clinical studies presented at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas showed that the
Read more →ICUIICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas ICU Medical, Inc. (Nasdaq: ICUI) today announced that it will initiate the full market release of the MicroCLAVE Clear Neutral Displacement...
SAN CLEMENTE, Calif. , March 31, 2011 /PRNewswire-FirstCall/ -- ICU Medical, Inc. (Nasdaq: ICUI ) today announced that it will initiate the full market release of the MicroCLAVE Clear Neutral Displacement Needlefree Connector at the Annual Scientific Meeting of the Society for He
Read more →Competitive Position
How ICUI ranks across every disease it competes inCompetitive Position is a premium feature
See how ICUI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial